Funding Disclosures in 2023NRAS would like to thank the following companies for supporting the work of NRAS during 2023 and acknowledge financial payment of any consultancy work provided by NRAS to the work undertaken by industry partners.Company NameProject Name/Reason for FundingMonthAmountBeneficiaryTotal 2023 Funding (ex VAT)AbbVie LtdNRAS attendance at Advisory Board MeetingFeb£560AbbVieCore FundingJul£10,000NRASNRAS attendance at Advisory Board MeetingDec£510AbbVie£11,070Biogen Idec LimitedPublication Funding for print and distribution of ‘I Want to Work’Sep£10,000NRASCorporate MembershipSep£12,000NRAS£22,000Eli Lilly and Company LimitedNRAS CEO presentation at nurse training eventNov£990Eli Lilly£990Fresenius Kabi LimitedPro-bono training (5 x remote sessions delivered to NRAS staff at a total of 9 hours – not invoiced)N/AN/ANRASCorporate MembershipDec£12,000NRAS£12,000Galapagos Biotech LimitedSponsorship to cover some costs of attending BSR conferenceMar£2,000NRASPeople’s Priority Magazine insert in NRAS NewsRheum MagazineMar£500Co-beneficiariesCorporate MembershipApr£12,000NRAS£14,500Inmedix Inc.NRAS Stress Matters project Jun£11,317.33NRAS£11,317.33Medac Pharma LLPSponsorship to cover some costs of attending BSR conferenceFeb£2,000NRASSelfie Frame for BSR conferenceMay£538NRASNRAS support on Injectable Project Focus GroupsNov£3,495MedacReprint of 2,000 Blood Matters bookletsApr£2,285NRAS£8,318Pfizer LimitedPatient recruitment for projectFeb£162Pfizer£162Sandoz LimitedNRAS attendance at Patient Advocacy Group EventSep£487.50SandozPublication Funding for print and distribution of ‘Employers’ Guide to RA’Nov£10,000NRAS£10,487.50UCB Pharma LtdCorporate MembershipJun£12,000NRAS£12,000Total funding received from the pharmaceutical industry in 2023: £102,844.83